MedPath

Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus

Phase 3
Completed
Conditions
Endometrial Cancer
Sarcoma
Registration Number
NCT00002459
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether receiving radiation therapy or no further therapy after surgery is more effective for cancer of the uterus.

PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with that of no further therapy in treating patients who have stage I or stage II cancer of the uterus that has been surgically removed.

Detailed Description

OBJECTIVES: I. Compare the rates of pelvic recurrence and development of distant metastases in patients with completely resected, stage I or II, high-grade uterine sarcoma treated with adjuvant pelvic radiotherapy vs observation alone.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center, tumor histology (leiomyosarcoma vs mixed mesodermal sarcoma vs endometrial stromal sarcoma), and surgical procedure (total abdominal hysterectomy (TAH) with or without bilateral salpingo-oophorectomy (BSO) vs TAH and BSO with pelvic and para-aortic node sampling and random biopsies). Patients are randomized to 1 of 2 treatment arms. Arm I: Beginning within 6 weeks after surgery, patients undergo pelvic radiotherapy 5 days a week for 5.6 weeks. Arm II: Patients undergo observation alone. Patients are followed every 2 months for 1 year, every 3 months for 2 years, and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 200 patients (100 per arm) will be accrued for this study within 3 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
224
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (28)

Instituto Valenciano De Oncologia

🇪🇸

Valencia, Spain

Ospedale Civile

🇮🇹

Voghera (PV), Italy

University Hospital of Linkoping

🇸🇪

Linkoping, Sweden

Centre Henri Becquerel

🇫🇷

Rouen, France

Karolinska Hospital

🇸🇪

Stockholm, Sweden

Rotterdam Cancer Institute

🇳🇱

Rotterdam, Netherlands

Derbyshire Royal Infirmary

🇬🇧

Derby, England, United Kingdom

Tom Baker Cancer Center - Calgary

🇨🇦

Calgary, Alberta, Canada

CHUS-Hopital Fleurimont

🇨🇦

Fleurimont, Quebec, Canada

Hopital Cantonal Universitaire de Geneva

🇨🇭

Geneva, Switzerland

Beatson Oncology Centre

🇬🇧

Glasgow, Scotland, United Kingdom

Academisch Ziekenhuis Utrecht

🇳🇱

Utrecht, Netherlands

Istituto Nazionale per lo Studio e la Cura dei Tumori

🇮🇹

Milan, Italy

Universita di Padova

🇮🇹

Padova, Italy

I.R.C.C.S. Policlinico San Matteo

🇮🇹

Pavia, Italy

Antoni van Leeuwenhoekhuis

🇳🇱

Amsterdam, Netherlands

University Hospital - Rotterdam Dijkzigt

🇳🇱

Rotterdam, Netherlands

Spedali Civili

🇮🇹

Brescia, Italy

Ospedale di Circolo e Fondazione Macchi

🇮🇹

Varese, Italy

Medisch Spectrum Twente

🇳🇱

Enschede, Netherlands

Academisch Ziekenhuis Maastricht

🇳🇱

Maastricht, Netherlands

University Medical Center Nijmegen

🇳🇱

Nijmegen, Netherlands

Istituto Scientifico H.S. Raffaele

🇮🇹

Milano, Italy

Ospedale San Gerardo

🇮🇹

Monza, Italy

Atrium Medical Centre

🇳🇱

Heerlen, Netherlands

Medical University of Gdansk

🇵🇱

Gdansk, Poland

U.Z. Gasthuisberg

🇧🇪

Leuven, Belgium

Vrije Universiteit Medisch Centrum

🇳🇱

Amsterdam, Netherlands

© Copyright 2025. All Rights Reserved by MedPath